Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 694,600 shares, a drop of 61.6% from the February 13th total of 1,810,000 shares. Based on an average trading volume of 3,830,000 shares, the short-interest ratio is presently 0.2 days. Approximately 4.7% of the company’s shares are sold short.

Hedge Funds Weigh In On Xilio Therapeutics

A number of large investors have recently modified their holdings of XLO. Aptus Capital Advisors LLC purchased a new stake in shares of Xilio Therapeutics in the fourth quarter worth approximately $39,000. Raymond James Financial Inc. bought a new stake in Xilio Therapeutics in the fourth quarter worth about $48,000. Trustees of Columbia University in the City of New York purchased a new stake in Xilio Therapeutics in the fourth quarter worth $238,000. Renaissance Technologies LLC increased its holdings in Xilio Therapeutics by 11.4% in the 4th quarter. Renaissance Technologies LLC now owns 296,617 shares of the company’s stock worth $283,000 after acquiring an additional 30,317 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after purchasing an additional 155,337 shares in the last quarter. 54.29% of the stock is currently owned by institutional investors.

Xilio Therapeutics Trading Up 4.1 %

XLO stock opened at $0.83 on Thursday. The stock has a 50-day moving average price of $0.94 and a 200-day moving average price of $0.94. Xilio Therapeutics has a 1-year low of $0.58 and a 1-year high of $1.93. The firm has a market cap of $36.27 million, a PE ratio of -0.48 and a beta of -0.38.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $1.72 million during the quarter, compared to analyst estimates of $2.26 million. On average, analysts forecast that Xilio Therapeutics will post -1.14 earnings per share for the current year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.